Taking the fight to inflammatory disease: InflaRx’s first-in-class C5a/C5aR signaling pathway strategy

Inflammatory diseases involve excessive or ongoing inflammation that damages tissues and affects many different human systems, including digestion, immunity, circulation, breathing, and the nervous system. The demand for anti-inflammatory treatments is growing quickly and is tipped to top a quarter of a trillion dollars within the decade as cases increase and new approaches to address inflammation emerge.This week, I had the chance to talk to Niels Riedemann, CEO and Founder of InflaRx, about his company’s first-in-class approach to fighting inflammation, and what the future might hold for his “pipeline in a product”.01:26   Introducing Niels Riedemann04:28   InflaRx and its mission06:37   The competitive landscape in anti-inflammatory therapeutics07:21   The market for anti-inflammatories08:40   The challenge of taking a drug from R&D to commercialization11:06   The science behind the C5a and C5aR approach14:37   Why is InflaRx the first to focus on these selective inhibitors?19:18   The importance of the MAC formation21:05   InflaRx and its disease targets25:46   Applications beyond anti-inflammatories27:50   Lessons learned from the clinic29:54   Growth forecasts for InflaRx31:48   Different approaches to addressing inflammation33:51   The role of academia in breakthrough therapies36:11   Beyond Europe and North America, addressing the global demand for therapeuticsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Why is the immunology and inflammation market suddenly attracting a wave of investment?Let’s Take a Closer Look at 7 Autoimmune Diseases Biotechs are Fighting to TreatJAK inhibitors: Are they a good option for treating inflammatory diseases and cancer?